<div id="readability-page-1">Belpointe Asset Management LLC lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 17.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,707 shares of the company's stock after selling 964 shares during the period. Belpointe Asset Management LLC's holdings in Eli Lilly and Company were worth $3,592,000 at the end of the most recent quarter.<div>Get Eli Lilly and Company alerts:</div><ul><li>3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026</li></ul>Several other institutional investors have also recently made changes to their positions in LLY. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company in the second quarter valued at $27,000. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $29,000. Steph &amp; Co. grew its position in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph &amp; Co. now owns 39 shares of the company's stock valued at $30,000 after acquiring an additional 29 shares during the period. Financial Gravity Companies Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $31,000. Finally, Bare Financial Services Inc raised its holdings in Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company's stock worth $31,000 after purchasing an additional 29 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors. <h2>Eli Lilly and Company Price Performance</h2>Shares of NYSE LLY opened at $1,063.34 on Tuesday. The firm has a 50-day simple moving average of $1,057.99 and a 200-day simple moving average of $883.36. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 52.02, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. <ul><li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li></ul>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts' expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company's revenue was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year. <h2>Eli Lilly and Company Increases Dividend</h2>The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company's payout ratio is 29.35%. <h2>More Eli Lilly and Company News</h2><ul><li>A Fresh IPO That Long-Term Investors Shouldn’t Ignore</li></ul>Here are the key news stories impacting Eli Lilly and Company this week:<ul> <li>Positive Sentiment: New marketing push around “weight stigma” aims to protect brand positioning for Lilly’s obesity medicines as competition heats up; could help demand/market share if effective. Eli Lilly’s (LLY) New Marketing Focuses on ‘Weight Stigma’</li> <li>Positive Sentiment: Guggenheim cut its price target to $1,161 but reiterated a Buy rating — indicates analysts still see upside, though expectations have been tempered. Guggenheim reduces PT on Eli Lilly and Company (LLY) to $1,161, reiterates 'Buy' rating</li> <li>Neutral Sentiment: Comparative features evaluating Lilly vs. peers (e.g., Viking, Novo Nordisk) keep LLY in investor conversations but don’t change fundamentals immediately. Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?</li> <li>Neutral Sentiment: Small institutional trimming: Commerzbank disclosed a minor sale (741 shares) in its latest filings — not material alone but part of regular portfolio moves. Eli Lilly and Company $LLY Shares Sold by Commerzbank Aktiengesellschaft FI</li> <li>Negative Sentiment: Major hospital trade group (AHA) and other hospital stakeholders are urging the Health Resources &amp; Services Administration to block Lilly’s expanded 340B claims-data submission policy — potential for regulatory intervention, disrupted hospital relationships, and reimbursement disputes. AHA urges HRSA to stop Eli Lilly’s 340B claims-data submission policy from going into effect</li> <li>Negative Sentiment: Press coverage (STAT) highlights hospital calls for the administration to block Lilly’s 340B policy — amplifies reputational and operational risk and increases near-term uncertainty around drug access for covered entities. Hospital group wants Trump administration to block a new Lilly policy on 340B claims data</li> <li>Negative Sentiment: Lilly’s own expansion of 340B reporting requirements is drawing pushback from hospitals — the company action intended for transparency could trigger contractual, pricing or access disputes. Eli Lilly to expand 340B reporting requirements</li> <li>Negative Sentiment: Analysis arguing Novo Nordisk may be regaining ground vs. Lilly highlights intensifying competition in weight-loss/diabetes markets — a longer-term pressure on pricing and market share. Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog</li> </ul><h2>Wall Street Analysts Forecast Growth</h2>Several analysts have commented on the company. Weiss Ratings reissued a &#34;buy (b-)&#34; rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Morgan Stanley increased their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, November 24th. Erste Group Bank raised shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Tuesday, October 14th. Sanford C. Bernstein reaffirmed an &#34;outperform&#34; rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Finally, Scotiabank initiated coverage on shares of Eli Lilly and Company in a research report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $1,165.00 target price on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of &#34;Buy&#34; and a consensus target price of $1,174.61.View Our Latest Stock Analysis on LLY<h2>About Eli Lilly and Company</h2> (Free Report)Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.<h2>Featured Stories</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>Do not delete, read immediately</li><li>The $100 Trillion AI Story No One Is Telling You</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li></ul><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>Before you consider Eli Lilly and Company, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.While Eli Lilly and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

Belpointe Asset Management LLC reduced its stake in Eli Lilly and Company (NYSE: LLY) by 17.0% in Q3, now holding 4,707 shares valued at $3,592,000. Other institutional investors also adjusted their positions. Eli Lilly's stock opened at $1,063.34, with a market cap of $1.01 trillion. The company reported Q3 earnings of $7.02 EPS, exceeding estimates, and announced a dividend increase to $1.73 per share. Analysts predict an EPS of 23.48 for FY 2025, with Guggenheim maintaining a 'Buy' rating despite lowering the price target to $1,161.

Market Beat

Direxion S&P Biotech Bear 3X

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

ChinaAMC SSE Health Care ETF Initiating Fund

Proshares UltraShort Nasdaq Biotech

Direxion Daily LLY Bear 1X Shares

iShares US Pharma

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Defiance Daily Target 2X Long LLY ETF

Health Care Select Sector SPDR

Eli Lilly and Company $LLY Shares Sold by Belpointe Asset Management LLC